NasdaqCM - Delayed Quote USD

Akebia Therapeutics, Inc. (AKBA)

Compare
1.3700 +0.0300 (+2.24%)
At close: October 21 at 4:00 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
174,497.0000
194,623.0000
292,484.0000
211,650.0000
294,644.0000
--
Cost of Revenue
65,327.0000
74,149.0000
85,568.0000
150,671.0000
296,477.0000
--
Gross Profit
109,170.0000
120,474.0000
206,916.0000
60,979.0000
-1,833.0000
--
Operating Expense
144,265.0000
166,549.0000
271,762.0000
325,481.0000
375,993.0000
--
Operating Income
-35,095.0000
-46,075.0000
-64,846.0000
-264,502.0000
-377,826.0000
--
Net Non Operating Interest Income Expense
-7,475.0000
-6,032.0000
-15,687.0000
-19,936.0000
-8,871.0000
--
Other Income Expense
2,128.0000
182.0000
-13,693.0000
2,414.0000
1,856.0000
--
Pretax Income
-40,442.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
--
Tax Provision
--
--
--
--
--
-6,631.0000
Net Income Common Stockholders
-40,442.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
--
Diluted NI Available to Com Stockholders
-40,442.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
--
Basic EPS
-0.21
-0.28
-0.51
-1.70
-2.77
--
Diluted EPS
-0.21
-0.28
-0.51
-1.70
-2.77
--
Basic Average Shares
198,231.1520
187,465.4480
182,782.6800
165,949.6950
138,463.1520
--
Diluted Average Shares
198,231.1520
187,465.4480
182,782.6800
165,949.6950
138,463.1520
--
Total Operating Income as Reported
-35,322.0000
-46,256.0000
-80,779.0000
-264,502.0000
-377,826.0000
--
Total Expenses
209,592.0000
240,698.0000
357,330.0000
476,152.0000
672,470.0000
--
Net Income from Continuing & Discontinued Operation
-40,442.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
--
Normalized Income
-41,899.0000
-51,220.0000
-77,387.0000
-282,024.0000
-384,841.0000
--
Interest Income
3,319.0000
--
--
--
--
--
Interest Expense
7,475.0000
6,032.0000
15,687.0000
19,936.0000
8,871.0000
--
Net Interest Income
-7,475.0000
-6,032.0000
-15,687.0000
-19,936.0000
-8,871.0000
--
EBIT
-32,967.0000
-45,893.0000
-78,539.0000
-264,502.0000
-377,826.0000
--
EBITDA
4,629.0000
-8,266.0000
-40,842.0000
-226,532.0000
-343,134.0000
--
Reconciled Cost of Revenue
65,327.0000
74,149.0000
85,568.0000
150,671.0000
296,477.0000
--
Reconciled Depreciation
37,596.0000
37,627.0000
37,697.0000
37,970.0000
34,692.0000
--
Net Income from Continuing Operation Net Minority Interest
-40,442.0000
-51,925.0000
-94,226.0000
-282,024.0000
-384,841.0000
--
Total Unusual Items Excluding Goodwill
1,457.0000
-705.0000
-16,839.0000
--
--
--
Total Unusual Items
1,457.0000
-705.0000
-16,839.0000
--
--
--
Normalized EBITDA
3,172.0000
-7,561.0000
-24,003.0000
-226,532.0000
-343,134.0000
--
12/31/2019 - 3/20/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers